This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.In fact, demand for these drugs has been so strong that it even surpassed supply until the drugmakers took action to scale up manufacturing capacit ...